Chemical inhibitors of Transmembrane protein 92-like precursor function through various molecular pathways, each targeting specific signaling cascades that can indirectly lead to its functional inhibition. LY294002 and Wortmannin, as inhibitors of PI3K, disrupt the PI3K/AKT pathway, a vital signaling route for cell survival and proliferation. This disruption can lead to the indirect inhibition of Transmembrane protein 92-like precursor by altering the cellular signaling dynamics, which are critical for the protein's functional state. Rapamycin and PP242, targeting the mTOR signaling pathway, modulate processes such as protein synthesis and autophagy. This modulation can indirectly inhibit Transmembrane protein 92-like precursor by changing the cellular environment and biochemical processes in which the protein is involved. Torin 1 also targets mTOR but affects both mTORC1 and mTORC2 complexes, impacting cellular growth and survival, and thereby the functional state of Transmembrane protein 92-like precursor.
The MAPK/ERK pathway, targeted by PD98059, U0126, Selumetinib, and PD0325901, represents another critical avenue for indirect inhibition. By disrupting the MEK component and, subsequently, the MAPK/ERK signaling, these inhibitors can lead to changes in gene expression and cellular differentiation processes, indirectly affecting the functional state of Transmembrane protein 92-like precursor. SB203580 and SP600125, by inhibiting p38 MAPK and JNK in the MAPK pathway, respectively, can potentially inhibit Transmembrane protein 92-like precursor by altering cellular stress responses and apoptotic pathways. Dactolisib, with its dual inhibitory action on both PI3K and mTOR pathways, represents a broader approach to modulating the cellular environment, potentially leading to the functional inhibition of Transmembrane protein 92-like precursor. These chemicals, through their targeted action on specific signaling pathways, collectively contribute to the functional inhibition of Transmembrane protein 92-like precursor, demonstrating the complex interplay and interconnectedness of cellular signaling networks.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, as a PI3K inhibitor, disrupts the PI3K/AKT pathway, which could indirectly inhibit Transmembrane protein 92-like precursor by altering cellular survival and proliferation signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTORC1, a key component in the mTOR signaling pathway. This inhibition could result in functional inhibition of Transmembrane protein 92-like precursor by modulating processes like protein synthesis and autophagy. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK inhibitor in the MAPK/ERK pathway, could indirectly inhibit Transmembrane protein 92-like precursor by disrupting downstream signaling involved in cell differentiation and proliferation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 targets p38 MAPK in the MAPK pathway, potentially inhibiting Transmembrane protein 92-like precursor by altering cellular stress responses and inflammatory pathways linked to its regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, by inhibiting MEK1/2 in the MAPK/ERK pathway, could indirectly inhibit Transmembrane protein 92-like precursor by modifying the cellular context, impacting cell differentiation and proliferation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, could indirectly inhibit Transmembrane protein 92-like precursor by influencing cellular survival and metabolic processes within the PI3K/AKT pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, as a JNK inhibitor in the MAPK pathway, could indirectly inhibit Transmembrane protein 92-like precursor by modulating cellular stress responses and apoptotic pathways. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242, a selective mTOR inhibitor, could indirectly inhibit Transmembrane protein 92-like precursor by altering cellular growth and survival processes within the mTOR signaling pathway. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
BEZ235, inhibiting both PI3K/mTOR pathways, could lead to functional inhibition of Transmembrane protein 92-like precursor by changing cellular proliferation and survival dynamics. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib, a MEK1/2 inhibitor, could functionally inhibit Transmembrane protein 92-like precursor by impacting cell growth and differentiation signals within the MAPK/ERK pathway. | ||||||